REG - Ilika plc - First Commercial Delivery to Cirtec Medical

IlikaAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260310:nRSJ9246Va&default-theme=true

RNS Number : 9246V  Ilika plc  10 March 2026

 

 

 

10 March 2026

Ilika plc

('Ilika,' the 'Company,' or the 'Group')

 

Ilika Announces Completion of First Commercial Delivery to Cirtec Medical

 

Electrode delivery signals further commercial progress

 

Ilika (AIM: IKA), the UK pioneer in solid state battery technology, announces
it has successfully delivered its initial batch of commercial grade
Stereax(Ò) electrode to Cirtec Medical (Cirtec) for Stereax M300 production.

 

In January 2026, Ilika that Cirtec had initiated the commercial electrode
supply arrangement with Ilika to support product manufacturing. Ilika has now
fulfilled the initial order, its first revenue-generating order from Cirtec.

 

The electrodes will be used in Stereax M300 batteries for validation and
customer sampling across a wide range of active implantable medical device
(AIMD) applications, including powering implanted sensors, neurostimulators,
orthopaedic implants, orthodontic wearables and ophthalmology devices.

 

Shawn Martin, Vice President at Cirtec Medical, said: "Our close technical
cooperation with Ilika has developed into an effective operational
partnership, ensuring our customers will receive the highest quality product
for integration into their devices. "

 

Graeme Purdy, CEO of Ilika, said: "This milestone demonstrates that Ilika's
facility in the UK can deliver commercial-grade electrodes to support Cirtec's
M300 manufacturing activities. We look forward to ramping our supply
activities to meet customer demand."

 

ENDS--

 

Enquiries:

 

 Ilika Plc                                             www.ilika.com (http://www.ilika.com/)
 Graeme Purdy, Chief Executive

                                                     Via FTI Consulting
 Jason Stewart, Chief Financial Officer

 Cavendish Capital Markets Limited (Nomad and Broker)  +44 (0)131 220 9772
 Peter Lynch

                                                     +44 (0)131 220 9771
 Neil McDonald

 FTI Consulting (Comms Advisors)                       ilika@fticonsulting.com

 Ben Brewerton

 Elizabeth Adams

 Dwight Burden

 

About Ilika plc

 

Ilika is a global expert in the development of solid-state battery technology
for electric vehicles, medical devices and consumer appliances. The Company's
pioneering next-generation technologies aim to provide scalable, affordable
alternatives to conventional batteries, to industries which need to
incorporate a smaller, lighter, and safer power source in their products.

 

The Company has two product lines. Its Stereax batteries are designed for
powering miniature medical implants, industrial wireless sensors and Internet
of Things (IoT) applications and the Goliath large format batteries are
designed for EV cars and cordless appliances.

 

Through its licensing business model, Ilika supplies its IP portfolio to both
OEMs and manufacturing partners in exchange for a license fee and future
royalties.

 

About Cirtec Medical‍

 

Cirtec Medical is a global leader in design, development, and manufacturing of
complex Class II and III medical devices, specializing inactive implant
systems, interventional devices, precision components, and thin film and
microelectronics. Since 1987, Cirtec Medical has built extensive in-house
capabilities that enable the company to serve as a single-source partner and
collaborate with customers to transform their technology into innovative
medical devices across a wide array of therapies, including cardiology,
neurology, orthopedics and other minimally invasive device applications.
Cirtec Medical's deep expertise in precision component design and
manufacturing supports every stage of the product lifecycle, ensuring
uncompromising quality and performance. With 11 global facilities and a
vertically integrated approach, Cirtec Medical aims to expedite time to
market, reduce risk, and accelerate revenue generation for our partners. Learn
more at CirtecMed.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCAKCBQABKDDNK



            Copyright 2019 Regulatory News Service, all rights reserved